Adherence to therapy of ixekizumab and secukinumab in psoriatic arthritis patients using first- or second-line IL-17A inhibitor treatment: A Danish population-based cohort study.
Rebekka L HansenTanja S JørgensenAlexander EgebergNana A L RosenøMarie SkougaardZara R StisenLene DreyerLars-Erik KristensenPublished in: Rheumatology (Oxford, England) (2023)
PsA patients receiving first- or second-line IL-17A inhibitors showed homogeneous baseline characteristics and similar adherence to therapy. Treatment failure of the first IL-17A inhibitor treatment should not preclude a second-line IL-17A inhibitor treatment.